{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}],"title":"Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}],"title":"Month 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"}],"units":"Participants"}],"description":"Grading of Acute GVHD:\n\nSeverity of Individual Organ Involvement:\n\nSkin\n\n* 1 a maculopapular eruption involving less than 25% of the body surface\n* 2 a maculopapular eruption involving 25-50% of the body surface\n* 3 generalized erythroderma\n* 4 generalized erythroderma with bullous formation and/or with desquamation Liver\n* 1 bilirubin 2.0-3.0mg/100mL\n* 2 bilirubin 3-5.9mg/100mL\n* 3 bilirubin 6-14.9mg/100mL\n* 4 bilirubin \\>15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea\n* 1 \\<1000mL of liquid stool/day\n* 2 \\>1,000mL of stool/day\n* 3 \\>1,500mL of stool/day\n* 4 2,000mL of stool/day, severe abdominal pain, with or without ileus\n\nSeverity of GVHD:\n\nGrade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver","groups":[{"description":"Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0\n\nTherapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.\n\nBusulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.\n\nIV Busulfan is available and diluted and administered per package insert guidelines.\n\nCyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including","id":"OG000","title":"Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)"}],"paramType":"NUMBER","populationDescription":"This is cumulative incidence of grades 2-4 aGVHD at 100 days and at 6 months. Out of the total number of participants, grades 2-4 aGVHD occurred in 79 patients.","reportingStatus":"POSTED","timeFrame":"Day 100, Month 6","title":"Acute Graft-Versus-Host Disease (aGVHD) Outcome","type":"SECONDARY","unitOfMeasure":"percentage of analyzed participants"}